

Announcement

Report on Extraordinary General Meeting held in NeuroSearch A/S

Pursuant to announcement, the Extraordinary General Meeting of NeuroSearch A/S was held today Monday, 3 May 2010. The following suggested amendments to the Articles of Association were finally adopted by the General Meeting:

- A.** The provision regarding the registered address of the company is cancelled
- B.** All statements of "aktiebog" are replaced with "ejerbog"
- C.** The Board of Directors is authorised to increase the company's share capital during the period ending on 28.04.2015 of total nominal sum of up to DKK 97,500,000 (4,875,000 shares of DKK 20 each)
- D.** In the period until 31.12.2011, the Board of Directors is authorised to issue warrants to the company's and its subsidiaries' employees, members of the Board of Directors and members of the Executive Management entitling the holders to subscribe for shares of the total nominal value of DKK 14,000,000 (700,000 shares of DKK 20 each)
- E.** In the period until 28.04.2015, the Board of Directors is authorised to raise loans of up to DKK 750,000,000 against issuance of convertible bonds which can be converted into a total nominal amount of up to DKK 97,500,000 (4,875,000 shares of DKK 20 each)
- F.** The keeper of the company's register of shareholders has changed its name from I-NVESTOR DANMARK A/S to Computershare A/S and the Articles of Association are amended accordingly
- G.** The proposed amendments to Articles 14(4) (deadline for minutes of the general meeting), 15 (deadline for submitting votes by letter), 16(2) (the removal of the requirement concerning quorum when deciding on changes to the Articles of Association) and 18a (guidelines for incentive payments) of the Articles of Association are made
- H.** The Board of Directors is authorised to re-number the articles in the Articles of Association.

Flemming Pedersen
CEO

Contact persons:

Flemming Pedersen, CEO, telephone: +45 4460 8214 or +45 2148 0118
Hanne Leth Hillman, Vice President, Director of IR & Corporate Communications,
telephone: +45 4460 8212 or +45 4017 5103

NeuroSearch – Company profile

NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on NASDAQ OMX Copenhagen A/S. The company's core business covers the development of novel drugs, based on a broad and well-established drug discovery platform focusing on ion channels and central nervous system (CNS) disorders. A substantial share of the activities is partner financed through strategic alliances with Eli Lilly and Janssen and a license collaboration with Abbott. The drug pipeline comprises eight clinical (Phase I-III) development programmes: Huntexil[®] for Huntington's disease (Phase III), tesofensine for obesity (Phase III), ABT-894 for ADHD (Phase II) in partnership with Abbott, ACR343 for schizophrenia (Phase II ready), ACR325 to treat dyskinesias in Parkinson's disease (Phase Ib), ABT-560 for the treatment of cognitive dysfunctions (Phase I) in collaboration with Abbott, NSD-788 for anxiety/depression (Phase I) and NSD-721 for social anxiety disorder (Phase I). In addition, NeuroSearch has a broad portfolio of preclinical drug candidates and holds equity interests in several biotech companies.

